CENTOGENE Reports Full Year 2022 Financial Results
May 16, 2023 18:25 ET
|
Centogene NV
Full Year 2022 total revenues with double-digit growth of 12% at €47.5 million, in line with prior guidanceSignificant expansion of gross profit margin from 32% to 42% and ongoing cost control...
CENTOGENE to Participate in Upcoming Conferences in May
May 05, 2023 06:30 ET
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 05, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and...
CENTOGENE to Participate in Upcoming Conferences in April
April 14, 2023 08:00 ET
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, April 14, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and...
CENTOGENE Appoints Ian Rentsch as Chief Commercial Officer and General Manager - Pharma
March 09, 2023 06:30 ET
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 09, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and...
CENTOGENE Regains Compliance With Nasdaq Listing Requirements
February 07, 2023 08:00 ET
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and...
CENTOGENE and Denali Therapeutics Extend World’s Largest Observational Study on Parkinson’s Disease Genetics
January 09, 2023 08:30 ET
|
Centogene NV
The Rostock International Parkinson's Disease (ROPAD) Study aims to characterize the genetics of PD to establish a better understanding of disease progression, diagnosis, and treatment for...
CENTOGENE Announces Its Attendance at the 41st Annual J.P. Morgan Healthcare Meeting and Fierce JPM Week in San Francisco
December 28, 2022 06:30 ET
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and...
CENTOGENE Reports Second Quarter and First Half 2022 Financial Results
December 22, 2022 16:00 ET
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and...
CENTOGENE Receives Nasdaq Non-Compliance Notice
December 16, 2022 16:30 ET
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and...
CENTOGENE to Participate in Upcoming Conferences in December
December 01, 2022 06:30 ET
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and...